



Jubilant Life Sciences Ltd.
1A, Sector 16A, Noida – 201301, India
Tel.: +91 120 4361000
www.jubl.com

Jubilant Life Sciences announces successful resolution to FDA Warning Letter for Montreal Facility

Noida (UP), India, Thursday, February 27, 2014

Jubilant Life Sciences Ltd, an integrated Pharmaceuticals and Life Sciences Company announced today that it has received a communication from the U.S. Food and Drug Administration (FDA), classifying its pharmaceutical manufacturing facility at Montreal, Canada as 'Acceptable'. This resolves all issues raised by the FDA on the facility in February 2013 and subsequent communications.

The development follows completion of FDA's review of the Company's responses post the February letter and the subsequent re-inspection conducted at Jubilant's Montreal facility in September, 2013. This development successfully resolves the FDA issues at our Montreal facility.

About Jubilant Life Sciences

Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Generics, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery and Development. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of over 6,300 multicultural people across the globe, the Company is committed to deliver value to its customers spread across 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com.

For more information please contact:

For Investors

Ravi Agrawal
Jubilant Life Sciences Limited
Ph: +91-120 436 1002
E-mail: ravi_agrawal@jubl.com

Siddharth Rangnekar
Citigate Dewe Rogerson
Tel: +91 22 6645 1209
E-mail: siddharth@cdr-india.com

Anupam Jain
Jubilant Life Sciences Limited
Ph: +91-120 436 1021

Karl Kolah
Citigate Dewe Rogerson
Tel: +91 22 6645 1220



E-mail: anupam_jain@jubl.com

E-mail: karl@cdr-india.com

For Media

Nidhi Malik
Jubilant Life Sciences Limited
Ph: +91-120 436 1062
E-mail: nidhi_malik@jubl.com

Sudipta Das
Perfect Relations
Ph: +91 9650602489
E-mail: sdas@perfectrelations.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.